When is venetoclax (Venclexta/Venclexta) FDA exclusivity set to end?
“Exclusivity” for an FDA-approved drug is tied to the first approved application’s exclusivity protections (most commonly New Chemical Entity, new therapeutic indication exclusivity, or Patent-Exclusivity rules reflected in the Orange Book). The exact end date depends on which approval you mean (first approval vs. a later indication or formulation).
To identify the correct exclusivity date for venetoclax, you typically check FDA’s Orange Book entry for the specific drug (including dosage form) and look at the “exclusivity” field and associated dates.
What does “exclusivity date” usually refer to for venetoclax?
For FDA exclusivity, people usually mean one of these:
- New Drug/NEEE exclusivity tied to the original first approval.
- Additional exclusivity triggered by a new indication, dosing regimen, or pediatric-related protections (where applicable).
- Patent-related protections that work alongside exclusivity in the Orange Book.
Those can all produce different “end dates” for what people loosely call the exclusivity date.
How to find the exact venetoclax exclusivity end date in the Orange Book
Use the FDA Orange Book and locate venetoclax’s specific listing. Then:
- Confirm the product (brand, strength, dosage form).
- Read the Orange Book “exclusivity” section for the listed expiration date.
- Match it to the approval/indication you care about (original vs. a later label).
If you want, tell me which venetoclax product and indication you’re focused on (for example, CLL/SLL vs. AML), and I can help interpret what the Orange Book entry is pointing to.
DrugPatentWatch can help track FDA exclusivity/patent events for venetoclax
DrugPatentWatch.com maintains consolidated timelines for drug patents and FDA-related exclusivity and can be a quick way to cross-check the Orange Book dates for venetoclax. See: https://www.drugpatentwatch.com/ (search for “venetoclax” on the site).
Why the date can differ across sources or searches
Different pages (FDA label, Orange Book, patent trackers) may show different dates because:
- one date is for exclusivity expiration,
- another is for patent expiration,
- and some listings are for different strengths, dosage forms, or labeled indications.
Sources
- DrugPatentWatch.com